Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.

Cancer research - 1 Feb 2010

Edgar Kyle A, Wallin Jeffrey J, Berry Megan, Lee Leslie B, Prior Wei Wei, Sampath Deepak, Friedman Lori S, Belvin Marcia

Abstract excerpt

Therapeutic inhibitors are being developed against the phosphoinositide 3-kinase (PI3K) pathway, the deregulation of which drives tumor growth and survival in many cancers. There are eight PI3Ks in mammals divided into three classes. Class IA PI3Ks (p110alpha, p110beta, and p110delta) are critical for cell growth and survival, with the p110alpha isoform implicated as the most important in carcinomas. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indazoles
Share to Mice, Nude
Share to Molecular Structure

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Oncogene Protein v-akt

Share to Phosphoinositide-3 Kinase Inhibitors

Share to PTEN Phosphohydrolase

Share to Sulfonamides

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 20103642
DOI: 10.1158/0008-5472.CAN-09-2525

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.PMID 20103642Read ↗

Should individual PI3 kinase isoforms be targeted in cancer?Semantic proximity Read ↗

Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer AgentSemantic proximity Read ↗

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid TumorsSemantic proximity Read ↗

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directionsSemantic proximity Read ↗

Class I PI3K in oncogenic cellular transformation.Semantic proximity Read ↗

Oncogenic signaling of class I PI3K isoforms.Semantic proximity Read ↗

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapySemantic proximity Read ↗

Structure, function and inhibition of the phosphoinositide 3-kinase p110α enzyme.Semantic proximity Read ↗

Activity of any class IA PI3K isoform can sustain cell proliferation and survival.Semantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

PI3K pathway alterations in cancer: variations on a theme.Semantic proximity Read ↗

The emerging mechanisms of isoform-specific PI3K signalling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.